Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Dyslipidemia

  Free Subscription


Articles published in Ann Intern Med

Retrieve available abstracts of 24 articles:
HTML format
Text format



Single Articles


    December 2017
  1. KOPIN L, Lowenstein C
    Dyslipidemia.
    Ann Intern Med. 2017;167:ITC81-ITC96.
    PubMed     Text format     Abstract available


  2. BURNS RB, Graham K, Sawhney MS, Reynolds EE, et al
    Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2017;167:786-793.
    PubMed     Text format     Abstract available


    August 2017
  3. NISSEN SE
    Statin Denial: An Internet-Driven Cult With Deadly Consequences.
    Ann Intern Med. 2017;167:281-282.
    PubMed     Text format    


    July 2017
  4. STAHEL P, Xiao C, Hegele RA, Lewis GF, et al
    Polygenic Risk for Hypertriglyceridemia Can Mimic a Major Monogenic Mutation.
    Ann Intern Med. 2017 Jul 25. doi: 10.7326/L17-0182.
    PubMed     Text format    


    June 2017
  5. RIDKER PM, Cook NR
    Cholesterol Evaluation in Young Adults: Absence of Clinical Trial Evidence Is Not a Reason to Delay Screening.
    Ann Intern Med. 2017;166:901-902.
    PubMed     Text format    


    May 2017
  6. PATEL KK, Taksler GB, Hu B, Rothberg MB, et al
    Prevalence of Elevated Cardiovascular Risks in Young Adults: A Cross-sectional Analysis of National Health and Nutrition Examination Surveys.
    Ann Intern Med. 2017 May 16. doi: 10.7326/M16-2052.
    PubMed     Text format     Abstract available


    January 2017
  7. LAUFFENBURGER JC, Shrank WH, Bitton A, Franklin JM, et al
    Association Between Patient-Centered Medical Homes and Adherence to Chronic Disease Medications: A Cohort Study.
    Ann Intern Med. 2017;166:81-88.
    PubMed     Text format     Abstract available


    October 2016
  8. COOK NR, Ridker PM
    Calibration of the Pooled Cohort Equations for Atherosclerotic Cardiovascular Disease: An Update.
    Ann Intern Med. 2016 Oct 11. doi: 10.7326/M16-1739.
    PubMed     Text format     Abstract available


    September 2016
  9. KHANJI MY, Bicalho VV, van Waardhuizen CN, Ferket BS, et al
    Cardiovascular Risk Assessment: A Systematic Review of Guidelines.
    Ann Intern Med. 2016 Sep 13. doi: 10.7326/M16-1110.
    PubMed     Text format     Abstract available


    April 2016
  10. TOBERT JA, Newman CB
    Management of Dyslipidemia for Cardiovascular Disease Risk Reduction.
    Ann Intern Med. 2016;164:509.
    PubMed     Text format    


  11. DOWNS JR, O'Malley PG
    Management of Dyslipidemia for Cardiovascular Disease Risk Reduction.
    Ann Intern Med. 2016;164:509-10.
    PubMed     Text format    


    March 2016
  12. NAVARESE EP, Kolodziejczak M, Kereiakes DJ, Tantry US, et al
    Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.
    Ann Intern Med. 2016 Mar 22. doi: 10.7326/M15-2994.
    PubMed     Text format     Abstract available


    January 2016
  13. TAYLOR WC
    Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease.
    Ann Intern Med. 2016;164:135.
    PubMed     Text format    


  14. LLOYD-JONES DM, Goff DC, Stone NJ
    Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease.
    Ann Intern Med. 2016;164:135.
    PubMed     Text format    


    November 2015
  15. SANTOS RD
    ACP Journal Club: ACC/AHA guidelines determining statin eligibility better predicted CVD than ATP-III guidelines.
    Ann Intern Med. 2015;163:JC11.
    PubMed     Text format    


    August 2015
  16. MITTLEMAN MA, Taylor WC, Smetana G, Burns RB, et al
    Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease: Grand Rounds Discussion From the Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2015;163:280-90.
    PubMed     Text format     Abstract available


  17. CORNELL JE, Mulrow CD
    Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.
    Ann Intern Med. 2015;163:242-3.
    PubMed     Text format    


  18. BATTAGGIA A, Donzelli A, Font M
    Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.
    Ann Intern Med. 2015;163:241-2.
    PubMed     Text format    


  19. LIAKOS A, Athanasiadou E, Mainou M, Bekiari E, et al
    Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.
    Ann Intern Med. 2015;163:241.
    PubMed     Text format    


    July 2015
  20. CAINZOS-ACHIRICA M, Martin SS, Cornell JE, Mulrow CD, et al
    PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?
    Ann Intern Med. 2015;163:64-5.
    PubMed     Text format    


    June 2015
  21. PATEL SA, Winkel M, Ali MK, Narayan KM, et al
    Cardiovascular Mortality Associated With 5 Leading Risk Factors: National and State Preventable Fractions Estimated From Survey Data.
    Ann Intern Med. 2015 Jun 30. doi: 10.7326/M14-1753.
    PubMed     Text format     Abstract available


  22. DOWNS JR, O'Malley PG
    Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
    Ann Intern Med. 2015 Jun 23. doi: 10.7326/M15-0840.
    PubMed     Text format     Abstract available


    May 2015
  23. LUCATORTO MA, Morgan S
    Effects of nurse-managed protocols.
    Ann Intern Med. 2015;162:669.
    PubMed     Text format    


    April 2015
  24. NAVARESE EP, Kolodziejczak M, Schulze V, Gurbel PA, et al
    Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
    Ann Intern Med. 2015 Apr 28. doi: 10.7326/M14-2957.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: